

16.11.2024. SATURDAY HALL A		
08:00-08:30	Sponsored symposium 1 BAYER Darolutamide in Prostate Cancer: Bridging Epidemiology and Pivotal trials Evidence Moderator: Zoran Džamić Understanding Prostate Cancer: Epidemiology, Pathophysiology, and the Role of Darolutamide - Zoran Džamić Examining the Evidence: Key Findings from ARAMIS and ARASENS Trials - Suzana Matković	
08:30-09:00	Sponsored symposium 2 MERCK Erbix & Bavencio – journey towards better outcome of oncology treatment Erbix in the continuum of mCRC treatment– 20 years of heritage – Marija Ristić Bavencio in the treatment of LA/mUC – long term follow up - Lazar Popović Discussion – all participants	
09:00-09:45	Scientific session 1 Multidisciplinary treatment of digestive tract malignancies – part 1: Gastric and gastroesophageal cancer Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić	
09:00-09:20	Modern systemic treatment of gastric and gastroesophageal cancer	Borislav Belev
09:20-09:35	Role of radiotherapy in treatment of locally advanced gastric and gastroesophageal cancer	Nikola Milošević
09:35-09:45	Panel discussion: Zoran Andrić, Dragan Gunjić, speakers	
09:45-10:30	Sponsored symposium 3 AMICUS Advancing Cancer Care: The Role of Nivolumab and Ipilimumab Ten-Year Outcomes of Nivolumab and Ipilimumab Combination Therapy in Melanoma – Suzana Matković Nivolumab in Urothelial Carcinoma: Clinical Outcomes and Future Directions – Lazar Popović Long-Term Outcomes of Nivolumab and Ipilimumab in Renal Cell Carcinoma: An 8-Year Follow-Up Study – Svetlana Salma Nivolumab in CheckMate 649: A Paradigm Shift in Gastric Cancer Treatment – Marija Ristić	
10:30-10:45	Coffee break	
10:45-11:30	Scientific session 2 Multidisciplinary treatment of digestive tract malignancies – part 2: Hepatocellular carcinoma Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić	
10:45-11:00	Locoregional treatments for hepatocellular carcinoma	Sanja Stojanović
11:00-11:15	Modern treatment algorithm for locally advanced hepatocellular carcinoma	Marija Ristić

11:15-11:30	Panel discussion: Mlađan Protić, Nenad Mijalković, Saša Jungić, speakers	
11:30-12:30	Sponsored symposium 4 ROCHE/Inpharm Navigating the patient journey in HCC treatment: challenges, achievements, and future perspectives Welcome and introduction - Ivan Nikolić The importance of surveillance and diagnosis - Nenad Mijalković What do the results from IMBrave150 reveal to us? - Ivan Nikolić What can we learn from the RWD? - Marija Ristić The impact of innovative therapy on improving treatment outcomes at KBC Zagreb - Borislav Belev Discussion - All participants	
12:30-12:45	Coffee break	
12:45-13:30	Scientific session 3 Multidisciplinary treatment of digestive tract malignancies – part 3: Cholangiocarcinoma Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić	
12:45-13:00	NGS in cholangiocarcinoma	Radmila Janković
13:00-13:15	Systemic treatment of locally advanced cholangiocarcinoma	Marina Marković
13:15-13:30	Panel discussion: Borislav Belev, Miljana Džunić, Ivan Nikolić, speakers	
13:30-14:00	Sponsored symposium 5 NOVARTIS Advancements and Challenges in mCRPC - Comprehensive approaches Moderator: Suzana Matković Speaker: Miloš Veljković	
14:00-15:00	Lunch	
15:00-16:15	Scientific session 4 Scientific projects in Serbia Moderators: Radmila Janković, Ivana Božović Spasojević	
15:00-15:15	Twinning to skyrocket scientific excellence towards individual radiosensitivity prediction by raising the bar in knowledge transfer, networking, and technological innovation in radiobiology - project: RadExIORSBoost, 101158832	Ivana Matić
15:15-15:30	Functional diagnostics in non-small cell lung carcinoma – a new concept for the improvement of personalized therapy in Serbian patients – project: TargetedResponse, 7739737	Milica Pešić
15:30-15:45	ADCs in oncology: why "magic bullet" does not mean "magic pharmacology"	Joseph Ciccolini
15:45-16:15	Discussion	
16:15-18:00	Scientific session 5 Translational research in radiobiology Moderators: Tatjana Stanojković, Marina Nikitović	
16:15-16:28	Biomarkers in radiobiology - challenges and future directions	Nađa Grozdanić Stanisavljević

16:28-16:41	Molecular Markers for Biological Dosimetry in Radiation Protection, Cancer Risk Assessment and Optimizing Radiotherapy	Igor Belyaev
16:41-16:54	RILA test in modern clinical practice	Jelena Stanić
16:54-17:07	The correlation between changes in the levels of IL-6 and TGF-B1 in serum and the occurrence of radiation toxicity in patients with prostate cancer	Katarina Kopčalić
17:07-17:20	Clinical Trials in Slovakia	Daniela Svetlovska
17:20-17:33	Different roles of SOX genes in promotion of malignant behavior of glioblastoma cells	Danijela Drakulić
17:33-17:46	MicroRNA – towards management of glioblastoma	Danijela Stanisljević Ninković
17:46-18:00	Discussion	
18:00-18:30	CLOSING REMARKS & evaluation	